O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov
- Authors: Knyazev OV1, Kagramanova AV1, Korneeva IA1, Noskova KK1, Belousov SV1, Parfenov AI1
-
Affiliations:
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow
- Issue: Vol 91, No 4 (2019)
- Pages: 53-61
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33596
- DOI: https://doi.org/10.26442/00403660.2019.04.000229
- ID: 33596
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O V Knyazev
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscowд.м.н., зав. отд-нием воспалительных заболеваний кишечника Moscow, Russia
A V Kagramanova
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscowк.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника Moscow, Russia
I A Korneeva
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscowм.н.с отд-ния воспалительных заболеваний кишечника Moscow, Russia
K K Noskova
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscowк.м.н., зав. лабораторным отделом Moscow, Russia
S V Belousov
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscowк.м.н., врач-эндоскопист отд-ния диагностической эндоскопии Moscow, Russia
A I Parfenov
A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow
Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника Moscow, Russia
References
- Фадеева Н.А., Корнеева И.А., Князев О.В., Парфенов А.И. Биомаркеры активности воспалительных заболеваний кишечника. Терапевтический архив. 2018;90(12):107-11. doi: 10.26442/00403660.2018.12.000018
- Hsu K, Champaiboon C, Guenther B.D, Sorenson B.S, Khammanivong A, Ross K.F, Geczy C.L, Herzberg M.C. Anti - infective protective properties of s100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009 Dec 4;8(4):290-305.
- Roseth A.G, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58(2):176-80.
- Осипенко М.Ф., Ливзан М.А., Скалинская М.И., Лялюкова Е.А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-3. doi: 10.17116/terarkh201587230-33
- Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro de Acosta M, Burisch J, Gecse K.B, Hart A.L, Hindryckx P, Langner C, Limdi J.K, Pellino G, Zagórowicz E, Raine T, Florian M.H. Third European Evidence - based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra - intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo - anal Pouch Disorders. J Crohn's Colitis. 2017;11(6):649-70. doi: 10.1093/ecco-jcc/jjx008
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;60(2):7-29.
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;59(1):6-30.
- Annese V, Daperno M, Rutter М.D, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018. doi: 10.1016/j.crohns.2013.09.016
- Schroeder K.W, Tremaine W.J, Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
- Best W.R, Becktel J.M, Singleton J.W, Kern F. Jr. Development of a Crohnʹs disease activity index. National Cooperative Crohnʹs Disease Study. Gastroenterology. 1976;70(3):439-44.
- De Suray N, Salleron J, Vernier-Massouille G, Grimaud J.C, Bouhnik Y, Laharie D, Dupas J.L, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, de Vos M, Piver E, Mary J.Y, Colombel J.F, Louis E. Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub analysis of the STORI study. J Crohn's Colitis. 2012;6(1):118-9. doi: 10.1016/S1873-9946(12)60294-3
- Van Rheenen P.F, van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta - analysis. BMJ. 2010;341:3369-80. doi: 10.1136/bmj.c3369
- Gisbert J.P. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66. doi: 10.1007/s00508-015-0915-3